MeSCue-Janusys aims is to improve cell therapy efficacy and safety, by offering a minimally invasive approach through the administration of NEXT generation Umbilical Cord Blood-derived Mesenchymal Stem Cells (UCB-derived MSCs) with both intravenous and local route of administration.

Mesenchymal Stem Cells (MSCs) Clinical Research

Because highly regenerative stem cells such as Embryonic Stem Cells (ESCs) or Induced Pluripotent Stem Cells (iPSCs) are not yet ready for the clinical application, allogeneic young MSCs isolated from Umbilical Cord Blood (UCB-derived MSCs) are the best and immediate candidates for clinical cell therapy in patients with unmet medical needs. MeSCue-Janusys company is developing cellular solutions for neurodegenerative diseases and other unmet medical needs with focus on the development of allogeneic UCB-derived MSCs.

Currently, our company is working to develop NEXT generation of MSCs with higher therapeutic potential by applying the most innovative technologies for the isolation and expansion of UCB-derived MSCs.

Therapeutic Targets

CNSD: Central Nervous System Diseases

Auto-ID: Autoimmune Diseases

ID: Inflammatory Disease

〒103-0023 東京都中央区日本橋本町3-11-5

  • Picture1
  • Picture3
  • Google maps
  • White LinkedIn Icon

Copyright@2019 MeSCue-Janusys Inc. All Rights Reserved